The Dip and Read Protein G biosensor from ForteBio, Inc. (Menlo Park, CA) rapidly detects and quantifies numerous types of mammalian immunoglobulin (IgG), an antibody molecule, from solution, and runs on the label-free Octet instrumentation platform. Proprietary BioLayer Interferometry (BLI) technology uses optical biosensors to measure multiple interactions in parallel without the use of detection agents. The Octet platform consists of 8- and 16-channel instruments that accommodate 96- and 384-well assay formats. All Octet biosensors simplify kinetic characterization and quantitation, and are disposable, configured in a standard microplate format and coated with a proprietary biocompatible matrix.
FORTEBIO ANNOUNCES LAUNCH OF PROTEIN G BIOSENSOR FOR USE ON COMPANY’S OCTET® INSTRUMENTS
Company also Completes ISO Certification of Biosensor Manufacturing Facility
MENLO PARK, Calif. --- September 3, 2010 --- ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read™ Protein G biosensor for rapid detection and quantification of numerous types of mammalian immunoglobulin (IgG), an antibody molecule, from solution. Because it runs on the company’s label-free Octet instrumentation platform, the new biosensor enables such measurements with unprecedented speed, ease of use and cost-efficiency. The company also announced that it has completed International Standards Organization (ISO) certification of its biosensor manufacturing facility.
“Protein G uniquely binds to many mammalian IgGs, such as murine, goat, bovine and other IgGs, making it an important tool in antibody discovery, cell line development and production monitoring,” said Christopher Silva, ForteBio’s vice president of marketing. “Traditional IgG quantification methods for numerous species and subtypes using Protein G, however, are complicated, labor-intensive and time-consuming. Now, with ForteBio’s new Protein G biosensor, researchers can obtain highly specific binding information in real time, in a cost-effective and easy-to-use manner.” Mr. Silva also noted that the company’s Protein G biosensor can be regenerated and reused, for increased workflow flexibility and cost-efficiency.
The new biosensor comes with recombinant Protein G pre-immobilized on the surface and is ready to use on ForteBio’s Octet instruments. ForteBio’s Octet platform is based on the company’s proprietary BioLayer Interferometry (BLI) technology, which uses optical biosensors to measure multiple interactions in parallel, without the use of detection agents. The Octet platform consists of 8- and 16-channel instruments that accommodate 96- and 384-well assay formats. All Octet biosensors are designed to simplify kinetic characterization and quantitation by eliminating throughput and time-to-result limitations of traditional SPR-based assays and ELISA. The Octet biosensors are disposable, configured in a standard microplate format and are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.
To date over 2.5 million biosensor assays have been run on Octet systems, a testament to the high reproducibility, accuracy and robustness of the platform.
The company also announced that its biosensor manufacturing facility is now ISO 9001:2008-certified, underscoring the quality of its products.